» Articles » PMID: 15716284

The Initial Management of Stable Angina in Europe, from the Euro Heart Survey: a Description of Pharmacological Management and Revascularization Strategies Initiated Within the First Month of Presentation to a Cardiologist in the Euro Heart Survey...

Abstract

Aims: In order to assess adherence to guidelines and international variability in management, the Euro Heart Survey of Newly Presenting Angina prospectively studied medical therapy, percutaneous coronary intervention (PCI), and surgery in patients with new-onset stable angina in Europe.

Methods And Results: Consecutive patients, 3779 in total, with a clinical diagnosis of stable angina by a cardiologist were enrolled. After initial assessment by a cardiologist, 78% were treated with aspirin, 48% with a statin, and 67% with a beta-blocker. ACE-inhibitors were prescribed by the cardiologist in 37% overall. Revascularization rates were low, with only 501 (13%) patients having PCI or coronary bypass surgery performed or planned. However, when restricted to patients with coronary disease documented within 4 weeks of assessment, over 50% had revascularization performed or planned. Among other factors, the national rate of angiography and availability of invasive facilities significantly predicted the likelihood of revascularization, OR 2.4 and 2.0, respectively.

Conclusion: This survey shows a shortfall between guidelines and practice with regard to the use of evidence-based drug therapy and evidence that revascularization rates are strongly influenced by non-clinical, in addition to clinical, factors.

Citing Articles

Profiles of Hospitalized Patients with Angiographic Coronary Heart Disease in Taiwan during 2014-2016: Report of a Tertiary Hospital.

Lin W, Hung Y, Lin G, Lin C, Liou J, Cheng C Acta Cardiol Sin. 2021; 37(4):365-376.

PMID: 34257486 PMC: 8261704. DOI: 10.6515/ACS.202107_37(4).20210118F.


Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registry.

Lang I, Badr-Eslam R, Greenlaw N, Young R, Steg P Wien Klin Wochenschr. 2017; 129(23-24):879-892.

PMID: 28913755 PMC: 5860132. DOI: 10.1007/s00508-017-1248-1.


Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.

Hidalgo-Vega A, Ramos-Goni J, Villoro R Eur J Health Econ. 2013; 15(9):917-25.

PMID: 24122303 DOI: 10.1007/s10198-013-0534-8.


Short-term effects of ivabradine in patients with chronic stable ischemic heart disease.

Zaky H, Elzein H, Alsheikh-Ali A, Al-Mulla A Heart Views. 2013; 14(2):53-5.

PMID: 23983908 PMC: 3752876. DOI: 10.4103/1995-705X.115495.


Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease.

Hemingway H, Philipson P, Chen R, Fitzpatrick N, Damant J, Shipley M PLoS Med. 2010; 7(6):e1000286.

PMID: 20532236 PMC: 2879408. DOI: 10.1371/journal.pmed.1000286.